Director Health Economics & Outcomes Research (HE&OR)
August 7, 2018
Princeton, New Jersey
Full Time - Experienced
Health Care Safety/Epidemiology, Health Economics/Outcomes Research, Health Policy
This position is responsible for the development and execution of robust health economics and outcomes research studies and projects, aligned with medical affairs strategies. This position will be responsible for developing and executing robust HE&OR plans that are aligned with brand strategies, support product value propositions, and optimize market access. This role requires active participation in cross-functional teams (Global and US), strong leadership in HE&OR, significant clinical and commercial strategic thinking and the capability to manage multiple projects.
Significant cross-functional responsibilities and leadership with Global Market Access, Regional Medical Affairs, Legal, Channel Marketing, Account Management, Marketing and other departments.
Responsibilities will include, but are not limited to, the following:
Provide guidance in the development of strategies to demonstrate the value of disease/products within the Medical Affairs with a focus on outcomes meaningful to payer and clinical decision-makers.
Generate the evidence necessary to maximize the commercial value of product(s) by demonstrating product differentiation and economic value.
Ensure strategic alignment with other areas by actively collaborating with cross-functional teams.
Develop communication/publication strategies for given product and ensure all research is conducted with a high level of scientific rigor.
Ensure timely development of high quality deliverables (e.g. AMCP dossiers, cost-effectiveness & budget impact models and other supporting materials) to support the value proposition to our key customers.
Manage multiple projects and product budgets to target as directed as well as interact with vendors in the execution of HE&OR projects.
Interact with key customers (MCOs, Center for Medicare & Medicaid Services (CMS), medical experts, etc.) as needed to deliver value messages for product pricing and re-imbursement, and optimal utilization.
Publish and present research accomplishments at scientific conferences and forums.
As a member of the HE&OR team, contribute to department strategy and objectives as well as represent HE&OR on key initiatives.
Experience & Skills:
Graduate (PhD or Masters) degree in a relevant HE&OR discipline including health economics, outcomes research, health services research, public health, health policy.
Minimum of 5 years in the pharmaceutical industry or a managed care setting in the direct conduct of health economics and outcomes research studies preferred
Expert level knowledge of outcomes research methods, including study design and analysis.
Strong commercial and clinical strategic mindset.
Demonstrated experience conducting research directly with managed care organizations, physician groups, and/or employers is desired.
Demonstrated research accomplishments as evidenced by a history of peer-reviewed publications.
Excellent knowledge of managed care, managed care decision making and the healthcare environment.
Excellent written and verbal communication skills and strong computer skills.
Ability to work well in a team and cross-functional environment, as well as work independently with limited supervision.
Ability to travel.
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.
Daratumumab is in clinical development for additional multiple myeloma indications. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.
Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.